These findings suggest that the sorafenib insensitivity of SR HCC cells primarily stems from GPAT3-mediated de novo biosynthesis of TAG rather than the exogenous uptake of TAG or FFA. This evidence concerns the gene GPAT3 and hepatocellular carcinoma.